🇺🇸 FDA
Pipeline program

Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN

MEDOPP545

Phase 3 small_molecule active

Quick answer

Everolimus-ratiopharm® 2,5 mg Tabletten, GOSERELIN , ORSERDU 86 mg film-coated tablets, ORSERDU 345 mg film-coated tablets, LEUPRORELIN , DEXAMETHASONE , The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side. The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose microcrystalline, Magnesium stearate, Hypromellose., TRIPTORELIN for patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors. is a Phase 3 program (small_molecule) at Stemline Therapeutics B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Stemline Therapeutics B.V.
Indication
patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer progressing to endocrine therapy and CDK4/6 inhibitors.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials